Alogliptin, a potent and selective dipeptidyl pept...[Curr Opin Investig Drugs. 2008]

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 1

Click to change filter selection through MyNCBI.

1: Curr Opin Investig Drugs. 2008 Apr;9(4):402-13.Links

Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

Deacon CF.

University of Copenhagen, Department of Biomedical Sciences, Panum Institute, DK-2200, Copenhagen N, Denmark. deacon@mfi.ku.dk

Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA.

PMID: 18393107 [PubMed - indexed for MEDLINE]

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. [Eur J Pharmacol. 2008]
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. [Clin Ther. 2008]
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. [J Med Chem. 2007]
ReviewFrom the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. [Curr Opin Drug Discov Devel. 2008]
ReviewDipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. [Front Biosci. 2008]

Display Show

Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

Related Articles